COVID-19 is a disease caused by infection with SARS-CoV-2, a strain of coronavirus. Respiratory illness is the most common symptom associated with COVID-19 with a severity ranging from mild disease to life-threatening acute respiratory distress syndrome. Patients with advanced age, comorbidities such as obesity, diabetes and cardiovascular disease, or an immunocompromised state, are at increased risk for poor outcomes. COVID-19 was declared a pandemic by the World Health Organization (“WHO”) in 2020. According to the WHO, as of November 17, 2021, more than 253 million people have been infected and COVID-19 has caused more than 5.1 million deaths.

COVID-19 infects humans via the mouth and nasal cavity where it replicates and then progresses into the airways and lungs. The most common symptoms of COVID-19 are fever, dry cough and fatigue, and less common symptoms include soreness of body and throat, diarrhoea, headache, and reduced smell and taste. More severe cases can lead to loss/shortness of breath, chest pain, and potentially loss of speech or movement. It typically takes five to six days from infection until the symptoms show.

Mild-to-Moderate

+ 0 M

13,4M suffers from Psoriasis in the US, EU5 and Japan

PDE4 inhibitor

Dermatology market and include
topical roflumilast cream

PDE4 Market and include
topical roflumilast cream

Moderate-to-servere

= 0 M

People in the US suffer from Psoriasis

TNF-Q + 11-17

Plaque psoriasis and atopic
dermatitis

Acim quam ratem eos dis ma
doluptatist

Checkpoint-for Psoriasis

= 0 M

People in EU5 suffer from Psoriasis

Keratinoc

Exerting anti-inflammatory effect
reducing psoriasis scale formation

PDE4 Market and include
topical roflumilast cream

Substantial psychosocial impacts of living with psoriasis 

The burden of living with psoriasis is often underestimated. In addition to the direct clinical challenges of psoriasis, many patients with plaque psoriasis suffer substantial psychosocial impacts from their disease, including: social stigma, feelings of rejection and shame, guilt, impaired sexual intimacy, discrimination in the workplace, difficulty finding employment or working outside the home, financial hardships, increased work absenteeism and reduced productivity. 

 

Treatment of psoriasis 

Psoriasis can be managed by topical, oral, biological treatments as well as phototherapy. Depending on the severity of the disease, patients and health care professionals choose between these treatment options. However, many physicians and patients express a need for better oral treatments. UNION is developing oral orismilast, a next-generation phosphodiesterase type-4 (“PDE4”) inhibitor, for the treatment of psoriasis. Read more here

The prevalence of COVID-19 – two key unmet needs

The primary drivers of the continued prevalence and unmet need of COVID-19 are viral mutations, waning vaccine immunity, vaccine skepticism, and vaccine deployment globally. One could expect new treatments and alternative means of prophylaxis to remain in demand over the coming years to help ensure lower case rates, hospitalization rates and mortality rates associated with COVID-19.

UNION has identified two key unmet needs related to COVID-19 that are likely to persist in the foreseeable future.

  •  Prophylaxis for immunocompromised and high-risk populations. Due to limited efficacy of vaccination in certain populations, i.e., people with a poor immune system due to medication or underlying disease (for example, organ transplant patients, cancer patients receiving chemotherapy, or patients with chronic kidney disease), these populations continue to be at high risk of contracting COVID-19. Additionally, these patients are at higher risk of severe outcomes of infection and experience higher hospitalization and mortality rates.
  • Early treatment and prevention of disease progression. Antiviral agents and neutralizing antibodies are likely most beneficial for early treatment and disease progression.
 

There is high likelihood for continued prevalence of COVID-19 cases in the general population due to viral mutations, waning vaccine immunity, vaccine skepticism and issues with vaccine deployment globally.

Across both unmet needs, UNION expects a continued demand for new prophylactic agents and treatments to increase the diversity of drugs available

Read more about UNIONs prophylactic niclosamide agent to address these unmet needs here

Meet Robert who lives with a new kidney and is significantly affected after having contracted COVID-19.

“I would very much like to start working again, if my head and my ability to talk will ever feel better after having had COVID-19.”